VG
Vasantha Gowda
Also known as: Dr Vasantha Lakshmi Gowda
Guy's and St Thomas' NHS Foundation Trust, Bristol Royal Hospital for Children, University of Oxford, Royal College of Paediatrics and Child Health, Great Ormond Street Hospital
0000-0002-8367-5489
Employment
-
Bristol Royal Hospital for Children Consultant Paediatric Neurologist2013 - 2015
-
Great Ormond Street Hospital Locum Consultant Paediatric Neurologist2013 - 2013
-
Guy's and St Thomas' NHS Foundation Trust Consultant Paediatric Neurologist
Education
-
University of Oxford MSc in Evidence Based Health-Care
-
Royal College of Paediatrics and Child Health FRCPCH
Projects & Funding
Projects & funding information is unavailable.
Publications (39)
- Dystrophin isoform deficiency and upper‐limb and respiratory function in Duchenne muscular dystrophy Save
- Influence of Dystrophin Isoform Deficiency on Motor Development in Duchenne Muscular Dystrophy Save
- Observational study of changes to glucocorticosteroid prescribing patterns in duchenne muscular dystrophy in the UK over the last decade Save
- REVEAL-CP: Selective Screening of Pediatric Patients for Aromatic L-Amino Acid Decarboxylase Deficiency with a Guthrie Card and In Silico Structural Modeling of One Index Case. Save
- Joint Modelling of Growth and Motor Function Centiles in Corticosteroids Treated Boys With Duchenne Muscular Dystrophy Save
- Spinal presentations in children with spinal muscular atrophy type 1 following gene therapy treatment with onasemnogene abeparvovec – The SMA REACH UK network experience Save
- Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1 Save
- Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 Save
- Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain Save
- Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom Save